Amyloid-Journal of Protein Folding Disorders

Papers
(The H4-Index of Amyloid-Journal of Protein Folding Disorders is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
A second case of liraglutide-type localised amyloidosis219
Re-evaluation of Mayo 2004 and revised Mayo 2012 staging in patients with AL amyloidosis in the era of new therapies201
A case of asymmetric insulin-derived localised amyloid deposition associated with long-acting insulin analog administration95
Changes in the amyloid editorial board members and in editor positions81
Factors associated with financial toxicity in patients with transthyretin amyloidosis: results from Amyloidosis Research Consortium’s treatment affordability patient and caregiver survey62
Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis40
Neurofilament light chain as a biomarker for hereditary ATTR amyloidosis − correlation between neurofilament light chain and nerve conduction study34
Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases28
Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange26
Survey of amyloidosis cases among different free-living wild and zoo animals24
Reduction of cardiac AL amyloid deposition after complete response visualised by PiB-PET imaging24
Role of complementarity-determining regions 1 and 3 in pathologic amyloid formation by human immunoglobulin κ1 light chains21
Early cardiovascular autonomic failure in ATTRv predicts poor prognosis and may respond to disease-modifying therapy19
Treatment response measurements and survival outcomes in a cohort of newly diagnosed AL amyloidosis18
Abnormal global longitudinal strain and reduced serum inflammatory markers in cardiac AL amyloidosis patients without significant amyloid fibril deposition17
Clinical impact of beta-blocker withdrawal in transthyretin amyloid cardiomyopathy16
Factors associated with changes in serum transthyretin after treatment with tafamidis and outcomes in transthyretin cardiac amyloidosis16
0.041441917419434